Tag: physicians

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026...

- The INDIGO study met its primary and all key secondary endpoints with statistically significant results -

Mayo Clinic and Microsoft collaborate to develop a frontier AI model for healthcare

Collaboration aims to expand access to Mayo Clinic's trusted healthcare expertise and improve patient and clinician experiences ROCHESTER, Minn., and REDMOND, Wash., June 2, 2026 /PRNewswire/...

Physicians Subjected to Unreliable ‘Lie-Detector’ Tests, according to the Journal of American Physicians and Surgeons

Though polygraph ("lie detector") tests are too unreliable to be admissible in court, physicians may be forced to undergo them in Physician Health Programs

Stellarus Launches AtlasIQ, A New Foundation for Modern Healthcare

Platform unifies fragmented healthcare data and enables real-time, AI-ready intelligence across the payer ecosystemOAKLAND, Calif., June 2, 2026 /PRNewswire/ -- Stellarus, a healthcare technology company...

Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference

SECAUCUS, N.J., Aug. 15, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO...

OpenEvidence creates the first AI in history to score a perfect 100% on the United States Medical Licensing Examination (USMLE)

MIAMI, Aug. 15, 2025 /PRNewswire/ -- Knowledge-based assessments remain a foundation of medical education. However, leveraging these resources for learning requires detailed and verifiable...

Caris Life Sciences Demonstrates Scientific Rigor with Clinical Validation of FDA-Approved MI Cancer Seek®

IRVING, Texas, Aug. 15, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published...

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Dried Plasma Innovation Addresses Critical Global Need

Velico's FrontlineODP™ Spray Dried Plasma Achieves Key Milestone with First-in-Human Safety Trial BEVERLY, Mass., Aug. 14, 2025 /PRNewswire/ -- Trauma doesn't wait, and neither should...

Providence St. Joseph Hospital Foundation Establishes First-Ever Endowed Chairs to Advance Excellence in Cardiac and Cancer Care

Donor generosity provides lasting support for physician leadership, innovation and patient care in Orange County ORANGE, Calif., Aug. 13, 2025 /PRNewswire/ -- Today Providence St....

Abercrombie & Fitch Co. Pledges Financial Support for Nationwide Children’s Hospital’s Behavioral Health Initiatives

Funding will support behavioral health crisis services at Nationwide Children's Hospital and provide free educational resources through The Kids Mental Health Foundation. COLUMBUS, Ohio, Aug....

Positron Corporation Secures Multi-Unit Sale of PET-CT Scanners to Leading Cardiology Group

Niagara Falls, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leader in molecular imaging technology and services, today announced the sale of four (4) PET-CT 64-slice scanners to a nationally recognized nuclear cardiology group specializing in advanced cardiovascular diagnostics and interventional care.

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2025 and provided a business update. All dollar values are in U.S. dollars unless stated otherwise.

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsPhysicians

easyGroup enters online retail with launch of easyShop.com marketplace in partnership with OnBuy.com

Viral Sunglasses Brands in 2026: Why Quay Is Becoming a Go-To Choice for Trend-Driven Shoppers According to Consumer365

New Report Reveals 3 in 4 CRNAs Got a Raise Last Year While Most Remain Just One Good Offer Away from a Career Move